Protective Effects of Pioglitazone on Dextran Sodium Sulphate-Induced Colitis in Rats Effects of Pioglitazone on Dextran Sodium Sulphate-Induced Colitis
Iranian Journal of Pharmaceutical Sciences,
Vol. 14 No. 3 (2018),
1 July 2018
,
Page 1-12
https://doi.org/10.22037/ijps.v14.40634
Abstract
The aim of the present study is to investigate the preventive effect of pioglitazone on colitis induced with dextran sulfate sodium (DSS) in rats. Twenty-four male Sprague-Dawley rats weighing 180-200 g were randomized into four groups. Rats of the 1st group received only saline and served as normal group. Colitis was induced in the remaining 3 groups by 1.5% DSS administered in drinking water for 8 days. Group 2 received only saline p.o. for 30 days and served as DSS control group. Groups 3 and 4 received pioglitazone (PIO; 10 mg/kg/day, p.o.) and sulfasalazine (SUL; 300 mg/kg) respectively for 30 days. All animals were sacrificed 24 h after the last treatment. Serum levels of interleukin-2 (IL-2), interleukin-6 (IL-6), and interleukin-17 (IL-17) were measured. Levels of tumor necrosis factor-α (TNF-α), reduced glutathione (GSH) and malondialdhyde (MDA), were measured in colon tissue. Significant elevation in GSH levels and reduction in MDA and TNF-α levels in colon tissue were observed in pioglitazone and sulfasalazine treated group when compared with the DSS control group. Significant elevation in serum IL-2 and reduction in serum IL-6 and IL-17 were observed when compared with the DSS control group. Pioglitazone reduced DSS-induced colitis possibly via reduction of MDA, TNF-α, IL-6, and IL-17 levels.
- Colitis
- Pioglitazone
- Dextran sodium sulphate
- Rats
- Interleukin-6, TNF-α.
How to Cite
References
[2] Celinski K, Dworzanski T, Korolczuk A, Piasecki R, Slomka M, Madro A and Fornal R. Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J. Physiol. Pharmacol. (2011) 62: 347.
[3] Konturek P, Brzozowski T, Engel M, Burnat G, Gaca P and Konturek S. Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. Acta physiologica. Polonica. (2009) 60: 41.
[4] Zwolinska-Wcislo M, Brzozowski T, Budak A, Kwiecien S, Sliwowski Z, Drozdowicz D, Trojanowska D, et al. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. Acta physiologica. Polonica. (2009) 60: 107.
[5] Lang KA and Peppercorn MA. Promising new agents for the treatment of inflammatory bowel disorders. Drugs in R & D. (1999) 1: 237-244.
[6] Allison MC and Pounder RE. Cyclosporin for Crohn's disease. Aliment Pharmacol. Ther. (1987) 1: 39-43.
[7] Middleton S, Shorthouse M and Hunter J. Increased nitric oxide synthesis in ulcerative colitis. The lancet. (1993) 341: 465-466.
[8] Yotsuya S, Shikama H and Imamura M. Efficacy of the inflammatory cell infiltration inhibitor IS-741 on colitis induced by dextran sulfate sodium in the rat. Jpn. J. Pharmacol. (2001) 87: 151-157.
[9] Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, et al. Inhibition of inhibitor of κB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology (2005) 128: 108-120.
[10] Uko V, Thangada S and Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol. Res. Pract. (2012) 2012.
[11] Linares V, Alonso V and Domingo JL. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert Opin. Drug Saf. (2011) 10: 253-263.
[12] Katsanos KH, Voulgari PV and Tsianos EV. Inflammatory bowel disease and lupus: a systematic review of the literature. J. Crohns Colitis (2012) 6: 735-742.
[13] Oz HS, Chen T and de Villiers WJ. Green tea polyphenols and sulfasalazine have parallel anti-inflammatory properties in colitis models. Front immunol. (2013) 4: 132.
[14] Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391: 79-82.
[15] Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. (1996) 39: 665-668.
[16] Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. (1995) 270: 12953-12956.
[17] Celiński K, Dworzański T, Prozorow-Krol B and Korolczuk A. The role of PPAR-γ receptors in gastrointestinal inflammation diseases. Gastroenterol. Pol. (2009) 16: 51-56.
[18] Dworzanski T, Celinski K, Korolczuk A, Slomka M, Radej S, Czechowska G, Madro A, et al. Influence of the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, rosiglitazone and antagonist, biphenol-a-diglicydyl ether (BADGE) on the course of inflammation in the experimental model of colitis in rats. J. Physiol. Pharmacol. (2010) 61: 683.
[19] Andersen V, Christensen J, Ernst A, Jacobsen BA, Tjonneland A, Krarup HB and Vogel UB. Polymorphisms in NF-kappa B, PXR, LXR, PPAR gamma and risk of inflammatory bowel disease. World J. Gastroenterol. (2011) 17: 197-206.
[20] Hontecillas R, Horne WT, Climent M, Guri AJ, Evans C, Zhang Y, Sobral BW, et al. Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal immunology (2011) 4: 304-313.
[21] Stein C, Millan MJ, Shippenberg TS, Peter K and Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol. Exp. Ther. (1989) 248: 1269-1275.
[22] Kuru Karabas M, Ayhan M, Guney E, Serter M and Meteoglu I. The effect of pioglitazone on antioxidant levels and renal histopathology in streptozotocin-induced diabetic rats. ISRN Endocrinology. (2013) 2013.
[23] Yoshikawa T, Yamaguchi T, Yoshida N, Yamamoto H, Kitazumi S, Takahashi S, Naito Y, et al. Effect of Z-103 on TNB-induced colitis in rats. Digestion. (1997) 58: 464-468.
[24] Wadie W, Abdel-Aziz H, Zaki HF, Kelber O, Weiser D and Khayyal MT. STW 5 is effective in dextran sulfate sodium-induced colitis in rats. Int J Colorectal Dis. (2012) 27: 1445-1453.
[25] Ruiz-Larrea MB, Leal AM, Liza M, Lacort M and de Groot H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids. (1994) 59: 383-388.
[26] Beutler E, Duron O and Kelly BM. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. (1963) 61: 882-888.
[27] Brouckaert P, Libert C, Everaerdt B, Takahashi N, Cauwels A and Fiers W. Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology. (1993) 187: 317-329.
[28] Bancroft J, Stevens A and Turner D. Theory and practice of histological techniques: Churchill Livingstone New York. the text. (1996): 766.
[29] Rogler G and Andus T. Cytokines in inflammatory bowel disease. World J. Surg. (1998) 22: 382-389.
[30] Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 98:
694-702.
[31] Cooper HS, Murthy S, Shah R and Sedergran D.Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. (1993) 69: 238-249.
[32] Sánchez-Hidalgo M, Martín AR, Villegas I and de la Lastra CA. Rosiglitazone, a PPARγ ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur. J. Pharmacol. (2007) 562: 247-258.
[33] Vrublova E, Vostalova J, Ehrmann J, Palikova I, Vrbkova J, Vacek J, Cibicek N, et al. The phytogenic feed additive Sangrovit modulates dextran sulfate sodium-induced colitis in rats. Veterinarni Medicina (2010) 55: 610-618.
[34] Rahimian R, Zirak MR, Keshavarz M, Fakhraei N, Mohammadi-Farani A, Hamdi H and Mousavizadeh K. Involvement of PPAR γ in the protective action of tropisetron in an experimental model of ulcerative colitis. Immunopharmacol Immunotoxicol. (2016) 38: 432-440.
[35] Choo J, Lee Y, Yan X-j, Noh TH, Kim SJ, Son S, Pothoulakis C, et al. A novel peroxisome proliferator-activated receptor (PPAR) γ agonist 2-hydroxyethyl 5-chloro-4, 5-didehydrojasmonate exerts anti-inflammatory effects in colitis. J. Biol. Chem.. (2015) 290: 25609-25619.
[36] Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, et al. Peroxisome proliferator‐activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm. Bowel Dis. (2002) 8: 330-339.
- Abstract Viewed: 94 times
- IJPS_Volume 14_Issue 3_Pages 1-12 Downloaded: 27 times